“冠科系”新锐冲击港交所,翰思艾泰的“下一代双抗免疫治疗”能否大放异彩?

动脉网
29 Jul

2025年以来,港股创新药板块大爆发。三生制药、荣昌生物年内涨幅高达400%,诺诚健华、信达生物、康方生物、和铂医药等股价翻倍。与板块大涨同步,港股创新药ETF基金、港股通创新药ETF、恒生创新药ETF、港股创新药ETF、港股创新药ETF年内涨幅近90%。与此同时,创新药企赴港IPO热潮再起。截至7月9日,已有12家生物医药企业成功登陆港交所,超去年全年上市数量,其中不乏恒瑞医药、映恩生物等重磅...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10